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Abstract
Background: The VEGF family of ligands and receptors are intimately involved in tumor angiogenesis,
lymphangiogenesis and metastasis. The evaluation of VEGF ligand/receptor ratios may provide a more profound
understanding of the involvement of these proteins in colorectal tumour progression. The aim of this study was to
elucidate the role of the VEGF ligand/receptor ratios on tumour progression and metastasis in patients with
mismatch repair-proficient colorectal cancer.
Methods: Immunohistochemistry for VEGF-A, VEGF-B, VEGF-C, VEGF-D, VEGFR1, VEGFR2 and VEGF3 was carried out
on 387 mismatch repair-proficient colorectal cancers using a tissue microarray. Evaluation of immunoreactivity was
performed semi-quantitatively and the ligand/receptor expression ratio was obtained.
Results: An increased VEGF-A/VEGFR1 ratio, VEGF-A and VEGFR1 was linked to the presence of peritumoral
lymphocytic inflammation at the invasive front (p = 0.032; p = 0.005; p = 0.032, respectively). VEGFR1 expression
was related to poorer outcome in multivariable analysis with pT stage, pN stage, vascular invasion, and post-
operative therapy. A higher ratio of VEGF-A/VEGFR2 was linked to advanced TNM stage (p = 0.005) while VEGF-A
and VEGFR2 were elevated in tumours with an infiltrating tumour growth pattern (p = 0.006; p = 0.014; p = 0.006).
No effect of VEGF-A/VEGFR2, VEGF-A or VEGFR2 on survival time was noted.
Conclusions: Our findings highlight an involvement of VEGF-A, VEGR1 and VEGFR2 in events occurring at the
invasive tumour front and a potential prognostic role of VEGFR1 expression in mismatch repair-proficient colorectal
cancers. The VEGF-A ligand to VEGFR1 or VEGFR2 ratio may represent an alternative evaluation system for
identifying patients with poorer clinical outcome.
Background
Angiogenesis, the process of developing new blood ves-
sels from pre-existing vascular networks, is now a well-
described mechanism leading to the initiation and main-
tenance of tumours, and the promotion of metastasis at
secondary sites [1]. Hypoxia is a major activator of
angiogenesis in tumours [2]; the hypoxic state of cells
promotes the up-regulation of a variety of cytokines and
tumour suppressors, such as p53 and also of hypoxia-
inducible factor 1-alpha, primarily known for its ability
to activate Vascular Endothelial Growth Factor (VEGF)
expression [3].
The VEGF family of ligands and receptors includes
VEGF-A, VEGF-B, VEGF-C, VEGF-D, platelet derived
growth factor (PlGF) and VEGFR1, VEGFR2, VEGFR3
and neuropilin NP1 and NP2 [4]. The best characterized
of the VEGF family members is VEGF-A, whose binding
to VEGFR2 (FLK1) is the predominant mechanism
through which tumour cells promote angiogenesis.
VEGF-A/VEGFR2 binding activates RAS/RAF-1/MEK/
ERK phosphorylation as well as signalling through
PI3K/pAKT. In response to signalling activity, up-regu-
lation of downstream effectors such as mdm2, p53, p27,
endothelial nitric oxide, and Bcl-2 can occur as well as
inhibition of pro-apoptotic proteins caspase-9 and
APAF-1. The consequences of this binding are increased
vascular permeability, enhanced endothelial cell prolif-
eration as well as increased survival, migration and
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known about VEGFR1 (FLT1), it appears to function as
a negative regulator of angiogenesis [5]. VEGF-A is
expressed on vascular cells and binds to VEGFR1 with
an affinity that is much higher than that for VEGFR2.
However, VEGFA seems to induce much weaker tyro-
sine kinase activity in VEGFR1 possibly because of an
inhibitory sequence in the juxtamembrane domain that
represses VEGFR1 activity [6]. In keeping with this
observation, a model for VEGFR1 has been developed
whereby it could act as a decoy receptor to modulate
angiogenesis through its ability to sequester VEGFA
thereby reducing signaling through VEGFR2. VEGF-B
has also been found to bind to VEGFR1, although the
role of this interaction remains to be completely eluci-
dated. VEGFR3 is the specific receptor for VEGF-C and
-D and is predominantly found on lymphatic, but also
to a lesser extent, on vascular endothelial cells and also
on tumour cells [7]. Interestingly, VEGF-C along with
VEGF-A and a variety of pro-angiogenic cytokines have
been shown to be released from tumour associated
macrophages, whose infiltration is thought to be, at least
in part, responsible for the angiogenic switch in tumours
whereby the balance of pro- and anti-angiogeneic factors
favour a pro-angiogenic phenotype [8-10].
In 1971, the pioneering work by Folkman and collea-
gues led to the hypothesis that anti-angiogenic com-
pounds could be successfully applied as anti-cancer
therapies [11,12]. In fact, blocking of VEGF has been
shown to lead to normalization of the vasculature, thus
increasing the efficacy of both radiotherapy (by increas-
ing the partial oxygen pressure of cells) and also the
delivery of chemotherapeutic agents to target cells (by
decreasing vascular permeability) [13]. Currently, the
humanized monoclonal antibody Bevacizumab approved
for the treatment of patients with metastatic colorectal
cancer has been successful in improving overall survival
times in several randomized controlled studies while
other approaches such as the use of tyrosine kinase inhi-
bitors continue to be investigated [14,15]. VEGFR1
immunoreactivity in tumour cells has been correlated
with poor prognosis, metastasis and recurrence in a vari-
ety of tumour types including breast and lung cancers
[16-18]. Inhibitors of VEGFR1 activity, such as VEGFR1
antibodies or soluble VEGFR1 traps have been developed
for preclinical and clinical evaluation and have been
shown to suppress tumour growth by inhibiting expres-
sion of VEGF on both tumour and stromal cells [5].
Although several studies have evaluated one or more
of these VEGF ligands or their receptors by immunohis-
tochemistry and their potential prognostic value, still
lacking is a comprehensive analysis performed on a
large number of tumours from patients with full clinico-
pathological data taking into consideration the different
expression ratios between the VEGF ligands and their
receptors. Such an evaluation may provide a more pro-
found understanding of the involvement of these angio-
genic proteins in colorectal tumour progression,
particularly considering the known differences in bind-
ing affinities of VEGF ligands to their receptors. The
aim of this study was therefore to elucidate the prognos-
tic role of the VEGF ligand to receptor ratios and their
effects in tumour progression and metastasis on 387
patients with mismatch repair-proficient colorectal
cancers.
Methods
Patients
489 non-consecutive, unselected colorectal cancer
patients treated at the Stadtspital Triemli, Zürich, Swit-
zerland were initially entered into this study. Histomor-
phologic features were systematically re-reviewed from
the corresponding hematoxylin and eosin (H&E) stained
slides in all cases and included TNM stage (according to
the 6
th edition of the American Joint Committee on
Cancer staging manual), tumor grade, the presence of
vascular invasion, the tumor border configuration, the
presence of peritumoral lymphocytic infiltration, the his-
tologic tumor subtype and mismatch repair status.
Patients with mismatch repair-deficient tumours (n =
102) were excluded from the study. Clinical data were
retrieved from the patient records and included age,
gender, tumor location, follow-up and disease-specific
survival time, information on local recurrence and dis-
tant liver metastasis. Of the 387 patients with mismatch
repair-proficient colorectal cancers, 88 received post-
operative therapy. All patients were pre-operatively
untreated and all resections were complete. Patient
characteristics are summarized in Table 1.
Specimen characteristics
Formalin-fixed paraffin-embedded tissue blocks were
retrospectively retrieved from the archives of the Insti-
tute of Pathology, Stadtspital Triemli, Zürich, Switzer-
land and a tissue microarray including all 387 patients
was constructed from each colorectal cancer resection
specimen. From each patient, one representative tumor
block was punched from the tumor centre using a tissue
cylinder 0.6 mm in diameter. Tissue was brought into
one recipient paraffin block (3 × 2.5 cm) using a home-
made semi-automated tissue arrayer as described else-
where [19] 71 tissues from normal colorectal mucosa
were included as a control.
Assay Methods
Immunohistochemistry
Immunohistochemistry for VEGF ligands and receptors
was carried out. Briefly, the tissue microarray was
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cooker mediated antigen retrieval in 0.001 M ethylene-
diaminetetraacetic acid (EDTA) pH 8.0, endogenous
peroxidase activity was blocked using 0.5% H2O2 and
the sections were incubated with 10% normal goat
serum (Dako Cytomation, Carpinteria, CA) for 20 min.
The colorectal cancers were then incubated with pri-
mary antibody for for VEGF-A (Santa Cruz; USA;
1:300), VEGF-B (Santa Cruz; USA; 1:100), VEGF-C
( S a n t aC r u z ;U S A ;1 : 1 0 0 ) ,V E G F - D( S a n t aC r u z ;U S A ;
1:100), VEGFR1 (LabVision; USA; 1:100), VEGFR2
(Santa Cruz; USA; 1:1000) and VEGFR3 (Chemicon;
USA; 1:200). Subsequently, sections were incubated with
HRP-conjugated secondary antibody (DakoCytomation)
for 30 min at room temperature. For visualization of the
antigen, the sections were immersed in 3-amino-9-ethyl-
carbazole+substrate-chromogen (DakoCytomation) for
30 min, and counterstained with Gill’s Haematoxylin.
Negative controls underwent the identical procedure
with primary antibody omitted. Positive controls con-
sisted of tumours known to contain the protein of inter-
est. Additionally, internal positive controls for VEGF
ligands, such as inflammatory cells, needed also to be
present for immunohistochemistry to be considered
valid. The use of tissue for this study was approved by
the local Ethics Committee of the University Hospital of
Basel.
Evaluation
The evaluation of immunohistochemistry was performed
by an expert gastro-intestinal pathologist blinded to
patient outcome. Using a semi-quantitative scoring
method which describes the percentage of positive
tumour cells assigned to each case on 5% intervals
(from 0% to 100%). This scoring system has previously
been found to lead to significant inter-observer agree-
ment between independent pathologists, particularly
using tissue microarrays. Staining intensity for most
VEGF ligands and receptors was homogeneous and
therefore not assessed. For VEGF ligands, cytoplasmic
staining was assessed whereas receptor expression was
scored in both cytoplasm and membrane. Representative
immunostains for VEGF ligands and receptors are illu-
strated in Figure 1.
VEGF ligand/VEGF receptor ratio
VEGF ligand to receptor ratios were determined by uti-
lizing the percentage of immunoreactivity in both cases
and dividing expression of the ligand by that of the
receptor. The following ratios were explored: VEGF-A/
VEGFR1, VEGF-A/VEGFR2, VEGF-B/VEGFR1, VEGFR-
C/VEGFR2, VEGFR-C/VEGFR3, VEGFR-D/VEGFR2
and VEGF-D/VEGFR3. In the event that the expression
of the receptor was 0% which occurred in 40 cases for
VEGFR1, 4 cases for VEGFR2 and 40 cases for VEGFR3,
cases were removed from the study. Ratios >1.0 indicate
a higher expression of liga n dc o m p a r e dt or e c e p t o r
while ratios <1.0 describe tumours with greater expres-
sion of receptor compared to ligand.
Study Design
The study design is outlined in Figure 2. Resection spe-
cimens from 489 patients treated between 1988 and
1996 were collected, retrospectively. A tissue microarray
containing all cases was constructed. Immunohisto-
chemistry for VEGF ligands and receptors was carried
out and staining evaluated. Immunohistochemistry for
Table 1 Characteristics of patients with mismatch repair-
proficient colorectal cancer
Clinico-pathological feature Frequency n (%)
Gender (n = 381) Female 175 (45.9)
Male 206 (54.1)
Tumour location (n = 369) Left-sided 242 (65.6)
Right-sided 127 (34.4)
pT stage (n = 373) pT1-2 86 (23.1)
pT3-4 287 (76.9)
pN stage (n = 357) pN0 178 (49.9)
pN1-2 179 (50.1)
Tumour grade (n = 374) G1-2 289 (77.3)
G3 85 (22.7)
Vascular invasion (n = 374) Absent 267 (71.4)
Present 107 (28.6)
Tumour border configuration
(n = 374)
Pushing 195 (52.1)
Infiltrating 179 (47.9)
Peritumoural lymphocytic
infiltration (n = 374)
Absent 308 (82.4)
Present 66 (17.7)
Local recurrence (n = 377) Absent 208 (55.2)
Present 169 (44.8)
Liver metastasis (n = 387) Absent 313 (80.9)
Present 74 (19.1)
Post-operative therapy (n = 377) No 289 (76.7)
Yes 88 (23.3)
Survival time (n = 377) 5-year (%)
(95%CI)
58.9 (52-65)
*G1-G2: well and moderately differentiated tumours; G3: poorly differentiated
tumors
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Page 3 of 10Figure 1 Figure 1A-N. Different colorectal cancer samples with negative and positive staining for VEGF ligands (cytoplasmic) and receptors
(membraneous and/or cytoplasmic): VEGFA+ (A), VEGFA- (B), VEGFB+ (C), VEGFB- (D), VEGFC+ (E), VEGFC- (F), VEGFD+ (G), VEGFD- (H), VEGFR1+
(I), VEGFR1- (J), VEGFR2+ (K), VEGFR2- (L), VEGFR3+ (M) and VEGFR3- (N).
Figure 2 Study Design. 489 unselected patients were initially entered into this study. After tissue microarray construction,
immunohistochemistry for VEGF ligands and receptors, 102 mismatch repair-deficient cases were excluded. Analysis of VEGF ligand/receptor
ratio with clinico-pathological features and survival was performed on the remaining 387 mismatch repair-proficient cases.
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identified 102 cases of mismatch repair-deficient color-
ectal cancers which were excluded from the analysis.
The median follow-up time of patients with mismatch
repair-proficient tumours was 30 months (range 0 to
144 months), mean time between local recurrence and
surgery was 20.1 months. Outcome measure of interest
was cancer-specific survival time.
Statistical analysis
VEGF ligand/receptor ratios and their association with
categorical clinico-pathological features was performed
using the non-parametric Wilcoxon Rank Sum Test or
Kruskal Wallis test, where appropriate. Missing clinico-
pathological information was assumed to be missing at
random. Survival analysis was carried out using the
Kaplan-Meier and log-rank test. The assumption of pro-
portional hazards was verified by analyzing the correla-
tion of Schoenfeld residuals and the ranks of individual
failure times. Subsequently, multivariable Cox propor-
tional hazards regression analysis was carried out to
determine the independent prognostic effect of each
VEGF ligand, receptor or ratio with significant effects in
univariate analysis, after adjusting for the effects of pT,
pN and vascular invasion. Hazard ratios (HR) and 95%
confidence intervals (CI) were used to determine the
prognostic effect of each variable. Due to multiple test-
ing, a Bonferroni correction for multiple comparisons
indicated that only p-values < 0.0012 should be consid-
ered statistically significant. All analyses were carried
out using SAS (V9, The SAS Institute).
Results
Comparison of normal mucosa and colorectal cancer
Expression of all VEGF ligands and receptors was signif-
icantly greater in colorectal cancers compared to normal
colorectal mucosa (p < 0.001; Figure 3).
VEGF ligand/receptor ratios (Tables 2 and 3)
An increased VEGF-A/VEGFR1 ratio was observed in
patients with tumours presenting conspicuous peritu-
moural lymphocytic inflammation at the invasive front
(p = 0.032). When analyzing VEGF-A and VEGFR1
separately, an increase of both VEGF-A (p = 0.005), and
VEGFR1 (p = 0.032) was found in tumours with this
histological feature in comparison to those with absence
of inflammation. In univariate analysis pT, pN and vas-
cular invasion all demonstrated a significant effect on
outcome (p < 0.001, each). These features were included
into multivariable survival analysis to determine the
effect of the VEGF-A, VEGFR1 and VEGF-A/VEGFR1
ratio on prognosis after adjusting for these 3 features.
Figure 3 Differences in mean VEGF ligand and receptor expression in normal colorectal mucosa in comparison to colorectal cancers.
Standard error bars are shown.
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outcome, while the remaining established prognostic
factors also maintained their independent effect on out-
come (Table 4). VEGFR1 expression also was related to
poorer prognosis after adjusting additionally for post-
operative adjuvant therapy.
The ratio of VEGF-A/VEGFR2 was linked to TNM
stage (p = 0.005). The average VEGF-A/VEGFR2 ratio
was 3.85 in metastatic stage IV cases compared to 0.66 in
stage III and 1.63 in stages I and II. Increased expression
of this ratio was again observed in patients with tumours
showing an infiltrating tumour growth pattern (p =
0.006). When evaluating VEGF-A or VEGFR2 expression
separately and their relationship to the tumour border
configuration, a strong loss of VEGF-A (p = 0.014) and
VEGFR2 expression in tumours with infiltrating margin
(p = 0.006) was observed. However, no effect of VEGF-
A/VEGFR2 or VEGFR2 on survival time was noted.
Decreased expression of VEGF-C/VEGFR2 was
observed in more advanced TNM stage (p = 0.003).
However, the remaining VEGF-ligand/receptor ratios
were not related to either clinico-pathological features
nor with survival in either metastatic and non-metastatic
patients.
Discussion
This work appears to be the first to evaluate in a single
study the immunohistochemical importance of four
VEGF ligands with their corresponding receptors in an
expression ratio in colorectal cancer. The findings here
support a role, not only for VEGF-A, VEGFR1 and
VEGFR2 in tumour progression but most importantly of
a potential prognostic role of VEGFR1 expression in
mismatch repair-proficient colorectal cancer.
The ratio of VEGF-A to VEGFR1 and VEGFR2 as well
as the ratio of VEGF-C/VEGFR2 demonstrated the most
interesting effects of these angiogenic proteins on pro-
gression and survival. These results are similar to those
reported by Hanrahan et al. who investigated VEGF
ligands and their receptors at the mRNA level in nor-
mal, adenoma and colorectal carcinoma [20]. In their
study, they suggest that VEGF-A and VEGF-B may be
responsible for the initiation of tumour whereas VEGF-
A and VEGF-C are further expressed in order to main-
tain disease progression. They observed a significant
correlation between VEGF-A and tumour size but not
with tumour stage, lymphovascular invasion or metasta-
sis. In addition, they document a significant link
between VEGFR1 expression and tumour grade and
Table 2 VEGF-A/VEGFR1, VEGF-A/VEGFR2, VEGF-B/VEGFR1, and VEGF-C/VEGFR2 ratios and association with clinico-
pathological features in mismatch repair-proficient colorectal cancer.
VEGF-A/VEGFR1 VEGF-A/VEGFR2 VEGF-B/VEGFR1 VEGF-C/VEGFR2
P-value P-value P-value P-value
TNM stage I+II 13.7 ± 32.6;
1.0
0.198 1.63 ± 8.6;
1.0
0.005 11.2 ± 27.2;
1.0
0.867 2.6 ± 9.3;
0.8
0.003
III 13.0 ± 31.7;
1.0
0.66 ± 0.4;
0.95
8.1 ± 23.2;
1.0
0.58 ± 0.38;
0.68
IV 5.2 ± 19.7;
1.0
3.85 ± 16.3;
1.0
5.9 ± 20.0;
1.0
1.95 ± 8.8;
0.84
Tumour grade G1-2 10.7 ± 29.2;
1.0
0.704 2.05 ± 10.6;
1.0
0.179 8.0 ± 22.9;
0.98
0.956 1.51 ± 8.2;
0.79
0.06
G3 13.5 ± 32.2;
1.0
0.73 ± 0.4;
0.95
12.9 ± 29.7;
1.0
0.58 ± 0.4;
0.65
Vascular invasion Absent 13.2 ± 32.2;
1.0
0.276 2.2 ± 11.3;
1.0
0.38 10.7 ± 26.9;
1.0
0.078 1.6 ± 8.9;
0.75
0.412
Present 6.48 ± 22.0;
1.0
0.78 ± 0.36;
0.98
4.28 ± 15.2;
0.95
0.65 ± 0.38;
0.75
Tumour border configuration PM 12.4 ± 31.2;
1.0
0.211 1.35 ± 6.3;
1.0
0.006 9.8 ± 25.2;
1.0
0.244 1.2 ± 5.7;
0.79
0.326
IM 9.83 ± 27.6;
1.0
2.28 ± 12.2;
0.95
7.76 ± 23.2;
0.95
1.48 ± 9.04;
0.75
PTL infiltration Absent 9.73 ± 27.6;
1.0
0.032 1.56 ± 8.4;
1.0
0.074 8.09 ± 23.5;
1.0
0.356 1.01 ± 4.5;
0.78
0.235
Present 17.5 ± 36.6;
1.0
2.83 ± 13.6;
1.0
12.3 ± 27.5;
0.87
2.79 ± 14.7;
0.75
Mean ± SD, median values. Kruskal Wallis or Wilcoxon Rank Sum Test. PM = pushing/expanding margin; IM = infiltrating margin; PTL = peritumoral lymphocytic.
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Page 6 of 10Table 3 VEGF-C/VEGFR3, VEGF-D/VEGFR2, and VEGF-D/VEGFR3 ratios and association with clinico-pathological
features in mismatch repair-proficient colorectal cancer.
VEGF-C/VEGFR3 VEGF-D/VEGFR2 VEGF-D/VEGFR3
P-value P-value P-value
TNM stage I+II 6.0 ± 21.0;
0.95
0.265 1.8 ± 9.1;
1.0
0.55 6.6 ± 22.4;
1.03
0.981
III 3.99 ± 13.4;
0.79
0.94 ± 0.1;
1.0
13.2 ± 32.0;
1.05
IV 5.93 ± 19.7;
1.0
4.67 ± 18.8;
1.0
7.14 ± 23.3;
1.05
Tumour grade G1-2 5.28 ± 18.3;
0.95
0.116 2.46 ± 11.9;
1.0
0.274 8.34 ± 25.4;
1.05
0.317
G3 4.94 ± 18.1;
0.75
0.96 ± 0.17;
1.0
11.9 ± 30.5;
1.0
Vascular invasion Absent 4.56 ± 16.8;
0.95
0.928 2.2 ± 10.5;
1.0
0.53 8.75 ± 26.2;
1.0
0.158
Present 6.74 ± 21.4;
0.95
2.34 ± 11.6;
1.0
9.7 ± 27.1;
1.05
Tumour border configuration PM 3.9 ± 15.7;
0.95
0.349 1.82 ± 9.04;
1.0
0.172 7.62 ± 24.5;
1.0
0.437
IM 6.67 ± 20.7;
0.95
2.53 ± 12.3;
1.0
10.5 ± 28.3;
1.05
PTL infiltration Absent 6.15 ± 20.1;
0.95
0.733 1.96 ± 9.9;
1.0
0.538 10.6 ± 28.9;
1.0
0.575
Present 1.09 ± 1.5;
0.85
3.18 ± 14.4;
1.0
1.79 ± 3.0;
1.05
Mean ± SD, median values. Kruskal-Wallis or Wilcoxon Rank Sum Test. PM = pushing/expanding margin; IM = infiltrating margin; PTL = peritumoral lymphocytic.
Table 4 Multiple Cox regression analysis of VEGFR1 adjusting for T stage, N stage, vascular invasion as well as post-
operative adjuvant therapy
Feature HR (95%CI) P-value HR (95%CI) P-value
VEGFR1 Baseline 1.0 0.024 1.0 0.032
1-unit increase 1.009 (1.001-1.017) 1.009 (1.001-1.017)
pT stage pT1-2 1.0 <0.001 1.0 <0.001
pT3-4 5.67 (2.03-15.8) 5.79 (2.07-16.19)
pN stage pN0 1.0 <0.001 1.0 <0.001
pN1-2 4.81 (2.53-9.16) 5.1 (2.61-9.97)
Vascular invasion Absent 1.0 <0.001 1.0 <0.001
Present 2.82 (2.82-4.75) 2.93 (1.71-5.02)
Post-operative therapy None 1.0 0.562
Treated 0.85 (0.49-1.48)
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expression and lymph node positivity. Our findings of
an increased VEGF-A expression from normal tissue to
tumour, but a lack of association between expression
with advanced pT stage, metastasis and survival time
further support a role of VEGF-A in initiation and
tumour maintenance in colorectal cancer. Furthermore,
the combined analysis of VEGF-A with VEGFR1 and
their correlation with features of tumour progression
and adverse prognosis seem to implicate in particular
VEGFR1 and VEGFR2 in the progression of colorectal
cancer.
Inflammatory mediators have previously been shown
to have a significant effect on the process of angiogen-
esis through the up-regulation of certain cytokines as
well as of VEGF [10,21]. Not only does VEGF increase
vascularity at sites of inflammation but its production
by tumour cells results in the expression of inter-cellular
adhesion molecule-1 and vascular cell adhesion mole-
cule-1, thereby facilitating the adhesion of leukocytes to
endothelial cells [22]. Our results highlight a relation-
ship between the over-expression of VEGF-A as well as
VEGFR1 and the peritumoural lymphocytic inflamma-
tory response at the invasive tumour front. The inflam-
matory response at the tumour border has previously
been linked to the tumour border configuration, which
we recently underlined as an essential prognostic factor
in colorectal cancer [23]. The presence of a conspicuous
band of lymphocytes, as described by Jass and colleagues
is frequently associated with the presence of a pushing
tumour margin, and has been related to an increased
number of CD8+ tumour infiltrating lymphocytes and
to an improved survival time [24,25]. In this study, we
find that a greater VEGFR2 expression compared to
VEGF-A is possibly linked to the presence of an infil-
trating margin. Since an infiltrating tumour border con-
figuration is a histomorphologic feature closely
correlated to epithelial mesenchymal transition (EMT),
whereby tumour cell de-differentiation and loss of cell-
cell adhesion occurs at the invasive tumour front, our
results may implicate VEGFR2 in this process [26].
T h ev a s tm a j o r i t yo ft h el i t e r a t u r es u g g e s tag r e a t e r
invasion and metastatic phenotype in tumours expres-
sing these proteins [27-33]. In particular, several groups
have suggested a VEGFR1-dependent involvement in
EMT. Bates and colleagues used a spheroid culture sys-
tem recapitulating the structure of the colonic epithe-
lium during EMT. Their results find a significant
expression of VEGFR1, but not VEGFR2 in these cells
[34]. In pancreatic cancer, Yang and coworkers also
describe VEGFR1 mediated EMT [35] while in head and
neck squamous cell carcinoma (HNSCC), VEGFR2
expression has been linked to vasculogenesis and bud-
ding of tumour cells into new vessels [36]. Our results
additionally underline not only the expression of VEGF-
A as a possible step in tumour progression of colorectal
cancer, but more importantly that VEGFR1 and
VEGFR2 as well as their ratios with VEGF-A to play a
role in the events occurring at the invasive tumour
front.
Although VEGF-C and VEGF-D are known primarily
as lymphangiogenic proteins, less is known about their
prognostic effect in patients with colorectal cancer. Hu
and colleagues found that protein expression of VEGF-C
and VEGF-D was significantly increased from normal to
tumour tissues, a result which we confirm in our study.
Furthermore, an increased expression of both these pro-
teins was linked to lymph node metastasis and worse
survival time [37]. Kawakami et al. report that VEGF-B
and VEGF-C mRNA are significantly higher in tumours
with lymph node metastases and in tumours with lym-
phatic invasion [38] while Onogawa and colleagues
report an increased VEGF-C and VEGF-D expression at
the invasive tumour front [39]. Others have found a sig-
nificant association of these proteins with venous and
lymphatic invasion as well as with liver metastasis. A
recent report by Moehler et al. found that VEGF-D
expression correlated with lymph node metastasis and
interestingly, that VEGF-D expression was significantly
decreased following treatment with anti-EGFR mAb
both in vitro and in mouse xenograft models [40]. In
our study, a lower expression ratio of VEGF-C/VEGFR2
was linked to more advanced TNM stage.
Our study has several limitations. First it is a retro-
spective analysis of VEGF ligand and receptor expres-
sion and therefore should be investigated in a
prospective setting. Secondly, having used the tissue
microarray technique, it is possible that tumour hetero-
geneity was not completely taken into account. As an
immunohistochemistry study, inter-laboratory variation
may play a role in determining the reproducibility of
these findings. Also, having considered adjustment for
multiple testing in this study, the associations of VEGF
ligands and their receptors fall short of significance
although several strong trends were observed. Therefore,
our results necessitate confirmation by other, larger
study groups. Finally, we were unable to randomize our
patient cohort into test and validation subgroups due to
the lack of statistical power that this would elicit. Never-
theless, our study may still be a basis for prospective
approaches and worth to be validated in future studies.
Conclusions
The results of this study suggest that the VEGF ligand
to receptor ratio may be an informative method for
evaluating the effects of the s ea n g i o g e n i cp r o t e i n so n
tumour progression. Our findings further underline a
potential involvement of VEGF-A, VEGR1 and VEGFR2
Eppenberger et al. BMC Cancer 2010, 10:93
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Page 8 of 10in events occurring at the invasive tumour front and
highlight a possible prognostic role of VEGFR1 expres-
sion in mismatch repair-proficient colorectal cancers.
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